ITI Pharma & Healthcare Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 23-01-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
Nifty Healthcare Index - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 21.35 19.23 25.77 1.80 8,914.89
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option Jul 13, 2018 34.34 23.90 28.58 1.91 5,320.29
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 29.60 22.95 27.55 1.94 3,628.03
DSP Healthcare Fund - Regular Plan - Growth Nov 30, 2018 31.20 21.89 27.95 1.90 3,339.79
Mirae Asset Healthcare Fund -Regular Growth Jul 02, 2018 26.95 17.64 26.57 1.92 2,863.52

Fund Holdings as on 31-December-2024

  • Sun Pharmaceutical Industries Limited

  • Lupin Limited

  • Divi's Laboratories Limited

  • Aurobindo Pharma Limited

  • Suven Pharmaceuticals Limited

  • Apollo Hospitals Enterprise Limited

  • Max Healthcare Institute Limited

  • Torrent Pharmaceuticals Limited

  • Laurus Labs Limited

  • Dr. Reddy's Laboratories Limited

  • Alkem Laboratories Limited

  • Aster DM Healthcare Limited

  • Syngene International Limited

  • Orchid Pharma Limited

  • Mankind Pharma Limited

  • Granules India Limited

  • Piramal Pharma Limited

  • Neuland Laboratories Limited

  • Caplin Point Laboratories Limited

  • Ajanta Pharma Limited

  • IPCA Laboratories Limited

  • Shilpa Medicare Limited

  • Healthcare Global Enterprises Limited

  • Wockhardt Limited

  • Fortis Healthcare Limited

  • FDC Limited

  • Vijaya Diagnostic Centre Limited

  • HDFC Life Insurance Company Limited

  • Emcure Pharmaceuticals Limited

  • Supriya Lifescience Limited

  • Gland Pharma Limited

  • Yatharth Hospital And Trauma Care Services Limited

  • TREPS 01-Jan-2025

  • Sumitomo Chemical India Limited

  • Rainbow Childrens Medicare Limited

  • Cipla Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Onesource Specialty Pharma Limited

  • Strides Pharma Science Limited

  • Linde India Limited

  • Sai Life Sciences Limited

  • Net Receivables / (Payables)

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Business Support

  • Insurance

  • Pesticides & Agrochemicals

  • Miscellaneous

  • Industrial Gases & Fuels

View More

Fund Manager

  • Cash

  • Equity

View More

About ITI Pharma & Healthcare Fund

Scheme Analysis

ITI Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ITI Mutual Fund. It was launched on 08-Nov-2021 and currently has an AUM of ₹230.79 crore. ITI Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and Nifty Healthcare Index - TRI as secondary index.

The NAV of ITI Pharma & Healthcare Fund ended up ₹0.24(1.48%)yesterday to ₹16.5253.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The ITI Pharma & Healthcare Fund is managed by Dhimant Shah and Rohan Korde.

Fund House Contact

ITI House, 36, R K Shirodkar Marg, Parel Mumbai - 400 012

022-69153500
mfassist@itiorg.com
www.itiamc.com